INDRAMEDCO.NS
Indraprastha Medical Corporation Limited [INDRAMEDCO.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
INDRAMEDCO.NS Stock Summary
Top 10 Correlated ETFs
INDRAMEDCO.NS
Top 10 Correlated Stocks
INDRAMEDCO.NS
In the News
INDRAMEDCO.NS Financial details
Company Rating
Buy
Market Cap
22.04B
Income
1.13B
Revenue
12.03B
Book val./share
-
Cash/share
-
Dividend
3
Dividend %
1.69%
Employees
2.95K
Optionable
No
Shortable
Yes
Earnings
06 Feb 2024
P/E
15.69
Forward P/E
-
PEG
1.7
P/S
1.39
P/B
3.94
P/C
-
P/FCF
-
Quick Ratio
1.36
Current Ratio
1.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
12.28
EPS next Y
-
EPS next Q
-
EPS this Y
47.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
24.84%
Revenue last 5Y
7.65%
Revenue Q/Q
-3.32%
EPS Q/Q
-10.34%
-
-
-
-
SMA20
39.41%
SMA50
30.22%
SMA100
10.23%
Inst Own
-
Inst Trans
-
ROA
16%
ROE
52%
ROC
0.3%
Gross Margin
58%
Oper. Margin
12%
Profit Margin
9%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
80.5-253.85
52W High
-8.04%
52W Low
+190.81%
RSI
66
Rel Volume
0.54
Avg Volume
342.77K
Volume
184.37K
Perf Week
-5.2%
Perf Month
28.01%
Perf Quarter
49.33%
Perf Half Y
34.4%
-
-
-
-
Beta
0.739
-
-
Volatility
5.39%, 30.11%
Prev Close
-2.43%
Price
232.65
Change
0.02%
INDRAMEDCO.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 82.91 | 86.91 | 65.02 | 94.05 | 119.85 | |
| Net income per share | 3.1 | 4.76 | 0.25 | 6.39 | 9.4 | |
| Operating cash flow per share | 8.2 | 9.43 | 3.04 | 7.78 | 15.76 | |
| Free cash flow per share | 6.34 | 4.97 | 0.76 | 4.56 | 10.9 | |
| Cash per share | 2.42 | 2.75 | 3.23 | 7.72 | 14.78 | |
| Book value per share | 26.62 | 29.21 | 29.75 | 35.5 | 41.39 | |
| Tangible book value per share | 26.57 | 29.06 | 29.38 | 35.31 | 41.29 | |
| Share holders equity per share | 26.62 | 29.21 | 29.75 | 35.5 | 41.39 | |
| Interest debt per share | 2.65 | 1.64 | 0.85 | 0.58 | 0.74 | |
| Market cap | 3.66B | 3.11B | 4.92B | 5.35B | 7.06B | |
| Enterprise value | 3.71B | 3.04B | 4.75B | 4.99B | 6.57B | |
| P/E ratio | 12.89 | 7.12 | 211.28 | 9.13 | 8.2 | |
| Price to sales ratio | 0.48 | 0.39 | 0.83 | 0.62 | 0.64 | |
| POCF ratio | 4.87 | 3.59 | 17.65 | 7.51 | 4.89 | |
| PFCF ratio | 6.3 | 6.83 | 70.99 | 12.8 | 7.07 | |
| P/B Ratio | 1.5 | 1.16 | 1.8 | 1.65 | 1.86 | |
| PTB ratio | 1.5 | 1.16 | 1.8 | 1.65 | 1.86 | |
| EV to sales | 0.49 | 0.38 | 0.8 | 0.58 | 0.6 | |
| Enterprise value over EBITDA | 4.7 | 3.65 | 12.4 | 4.17 | 4.08 | |
| EV to operating cash flow | 4.93 | 3.52 | 17.03 | 7 | 4.54 | |
| EV to free cash flow | 6.38 | 6.68 | 68.52 | 11.93 | 6.57 | |
| Earnings yield | 0.08 | 0.14 | 0 | 0.11 | 0.12 | |
| Free cash flow yield | 0.16 | 0.15 | 0.01 | 0.08 | 0.14 | |
| Debt to equity | 0.09 | 0.05 | 0.03 | 0.02 | 0.01 | |
| Debt to assets | 0.05 | 0.03 | 0.02 | 0.01 | 0 | |
| Net debt to EBITDA | 0.06 | -0.08 | -0.45 | -0.3 | -0.31 | |
| Current ratio | 1.09 | 1.01 | 1.22 | 1.68 | 1.72 | |
| Interest coverage | 17.48 | 48.13 | 1.92K | 8.51K | 26.24 | |
| Income quality | 1.68 | 1.79 | 6.5 | 0.9 | 1.23 | |
| Dividend Yield | 0.04 | 0.06 | 0 | 0 | 0.03 | |
| Payout ratio | 0.57 | 0.41 | 0.11 | 0 | 0.27 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | -0.23 | -0.47 | -0.75 | -0.41 | -0.31 | |
| Capex to revenue | -0.02 | -0.05 | -0.04 | -0.03 | -0.04 | |
| Capex to depreciation | -0.57 | -1.24 | -0.63 | -0.84 | -1.14 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 43.09 | 55.93 | 13.04 | 71.47 | 93.55 | |
| ROIC | 0.13 | 0.17 | 0.01 | 0.19 | 0.21 | |
| Return on tangible assets | 0.07 | 0.1 | 0.01 | 0.13 | 0.16 | |
| Graham Net | -8.57 | -8.42 | -5.82 | -0.67 | 1.66 | |
| Working capital | 114.59M | 18.67M | 255.19M | 639.3M | 934.5M | |
| Tangible asset value | 2.44B | 2.66B | 2.69B | 3.24B | 3.78B | |
| Net current asset value | -427.78M | -397.2M | -177.75M | 211.6M | 473.9M | |
| Invested capital | 0.09 | 0.05 | 0.03 | 0.02 | 0.01 | |
| Average receivables | 1.06B | 974.34M | 964.02M | 841.54M | 703.45M | |
| Average payables | 812.72M | 973.59M | 977.47M | 842.53M | 874.65M | |
| Average inventory | 87.2M | 101.91M | 104.02M | 93.64M | 92.2M | |
| Days sales outstanding | 47.03 | 44.42 | 58.7 | 30.67 | 22.67 | |
| Days payables outstanding | 96.95 | 107.45 | 134.58 | 73.1 | 75.58 | |
| Days of inventory on hand | 8.86 | 12.5 | 12.82 | 9.51 | 6.5 | |
| Receivables turnover | 7.76 | 8.22 | 6.22 | 11.9 | 16.1 | |
| Payables turnover | 3.76 | 3.4 | 2.71 | 4.99 | 4.83 | |
| Inventory turnover | 41.19 | 29.21 | 28.48 | 38.36 | 56.11 | |
| ROE | 0.12 | 0.16 | 0.01 | 0.18 | 0.23 | |
| Capex per share | -1.86 | -4.46 | -2.29 | -3.22 | -4.86 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 30.29 | 29.81 | 33.44 | 34.58 | 33.43 | |
| Net income per share | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | |
| Operating cash flow per share | 2.15 | 2.15 | 2.14 | 2.19 | 2.19 | |
| Free cash flow per share | 2.15 | 2.15 | 2.14 | 2.19 | 2.19 | |
| Cash per share | 22.34 | 14.78 | 14.04 | 23.31 | 0 | |
| Book value per share | 37.47 | 41.39 | 41.39 | 45.24 | 0 | |
| Tangible book value per share | 0 | 41.29 | 0 | 45.18 | 0 | |
| Share holders equity per share | 37.47 | 41.39 | 41.39 | 45.24 | 0 | |
| Interest debt per share | 0.09 | 0.37 | 0.09 | 0.6 | 0.09 | |
| Market cap | 7.62B | 7.06B | 8.37B | 15.39B | 16.36B | |
| Enterprise value | 9.67B | 6.57B | 9.66B | 15.05B | 16.36B | |
| P/E ratio | 9.11 | 8.9 | 6.86 | 11.71 | 13.9 | |
| Price to sales ratio | 2.74 | 2.58 | 2.73 | 4.85 | 5.34 | |
| POCF ratio | 38.63 | 35.82 | 42.68 | 76.71 | 81.57 | |
| PFCF ratio | 38.63 | 35.82 | 42.68 | 76.71 | 81.57 | |
| P/B Ratio | 2.22 | 1.86 | 2.21 | 3.71 | 0 | |
| PTB ratio | 2.22 | 1.86 | 2.21 | 3.71 | 0 | |
| EV to sales | 3.48 | 2.4 | 3.15 | 4.75 | 5.34 | |
| Enterprise value over EBITDA | 24.08 | 17.31 | 19.01 | 27.61 | 31.73 | |
| EV to operating cash flow | 49.02 | 33.29 | 49.24 | 75.04 | 81.57 | |
| EV to free cash flow | 49.02 | 33.29 | 49.24 | 75.04 | 81.57 | |
| Earnings yield | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 | |
| Free cash flow yield | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0.01 | 0 | 0.01 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0 | |
| Net debt to EBITDA | 5.1 | -1.31 | 2.53 | -0.61 | 0 | |
| Current ratio | 0 | 1.72 | 0 | 1.46 | 0 | |
| Interest coverage | 34.8 | 32.26 | 48.01 | 52.35 | 47.75 | |
| Income quality | 0.94 | 0.99 | 0.64 | 0.61 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | -0.11 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 43.84 | 44.89 | 55.66 | 60.4 | 0 | |
| ROIC | 0.06 | 0.05 | 0.07 | 0.08 | 0 | |
| Return on tangible assets | 0 | 0.04 | 0 | 0.05 | 0 | |
| Graham Net | 22.34 | 1.66 | 14.04 | 1.76 | 0 | |
| Working capital | 2.05B | 934.5M | 1.29B | 954.6M | 0 | |
| Tangible asset value | 0 | 3.78B | 0 | 4.14B | 0 | |
| Net current asset value | 2.05B | 473.9M | 1.29B | 496.6M | 0 | |
| Invested capital | 0 | 0.01 | 0 | 0.01 | 0 | |
| Average receivables | 346.25M | 341.2M | 341.2M | 341.9M | 341.9M | |
| Average payables | 684.9M | 490.9M | 490.9M | 678.95M | 678.95M | |
| Average inventory | 52.25M | 42.25M | 42.25M | 39.8M | 39.8M | |
| Days sales outstanding | 0 | 22.47 | 0 | 19.41 | 0 | |
| Days payables outstanding | 0 | 75.78 | 0 | 90.75 | 0 | |
| Days of inventory on hand | 0 | 6.52 | 0 | 5.32 | 0 | |
| Receivables turnover | 0 | 4 | 0 | 4.64 | 0 | |
| Payables turnover | 0 | 1.19 | 0 | 0.99 | 0 | |
| Inventory turnover | 0 | 13.8 | 0 | 16.92 | 0 | |
| ROE | 0.06 | 0.05 | 0.08 | 0.08 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
INDRAMEDCO.NS Frequently Asked Questions
What is Indraprastha Medical Corporation Limited stock symbol ?
Indraprastha Medical Corporation Limited is a IN stock and trading under the symbol INDRAMEDCO.NS
What is Indraprastha Medical Corporation Limited stock quote today ?
Indraprastha Medical Corporation Limited stock price is $232.65 today.
Is Indraprastha Medical Corporation Limited stock public?
Yes, Indraprastha Medical Corporation Limited is a publicly traded company.
Company Profile
- Volume Average 342.77K
- Market Capitalization 22.04B
- Employee 2.95K
- CEO Mr. Shivakumar Pattabhiraman ACA, B Com, CWA, Grad.
- Headquarters New Delhi,IN
- IPO Date 1997-05-07
-
Website
https://www.delhi.apollohospitals.com 
Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of anesthesiology, pediatric, elder care, genomic medicine, health check, sugar, bariatric and metabolic surgery, bone marrow transplant, cancer, cardiac and cardiology, dermatology, dietetics and clinical nutrition, emergency care, endovascular surgery, endocrinology/diabetes care, ENT, fetal medicine, gastroenterology and hepatology, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedic, pediatric urology and pediatric surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology/radio diagnosis, respiratory sleep medicine and critical care, rheumatology, robotic surgery, spine surgery, transfusion medicine, transplant, and urology and andrology. The company operates cosmetic and dental clinics. Indraprastha Medical Corporation Limited was incorporated in 1988 and is based in New Delhi, India.
